Description: Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Home Page: www.calidibio.com
4475 Executive Drive
San Diego,
CA
92121
United States
Phone:
858 794 9600
Officers
| Name | Title |
|---|---|
| Mr. Allan J. Camaisa | CEO & Chairman of the Board |
| Ms. Wendy Pizarro Campbell Esq. | Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary |
| Dr. Boris Minev M.D., Ph.D. | President of Medical & Scientific Affairs and Interim Chief Medical Officer |
| Mr. Andrew C. Jackson | Chief Financial Officer |
| Mr. Stephen Thesing | Chief Business Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |